GLCE and prostate cancer: Treatment of the cells with DNA-demethylating agent 5-aza-deoxycytidine (aza-dC) did not affect the GLCE mRNA level in the PNT2 and DU145 cells but increased the level in the LNCaP (2-fold) and PC3 cells (3-fold), suggesting the possible involvement of promoter methylation in the differential expression of GLCE in prostate cancer cells.